AKCA Akcea Therapeutics Inc.

Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast

Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast

Webcast scheduled for Tuesday, May 5 at 4:30 p.m. Eastern Time

BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress.

Interested parties may listen to the call by dialing 888-317-6003, passcode 7102411, or access the webcast at . A webcast replay will be available for a limited time at the same address.

ABOUT AKCEA THERAPEUTICS

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen), as well as advancing a mature pipeline of novel drugs, including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil. WAYLIVRA is approved in the E.U. and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Boston, Massachusetts. Additional information about Akcea is available at  and you can follow us on Twitter at @akceatx. 

FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of Akcea’s drugs in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in Akcea’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the company.

In this press release, unless the context requires otherwise, “Ionis,” “Akcea,” “Company,” “Companies,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc., Akcea Therapeutics®, TEGSEDI® and WAYLIVRA® are trademarks of Akcea Therapeutics, Inc.

Media and Investor Contacts:

Angelyn Lowe

Executive Director of Corporate Communications and Investor Relations

442-287-0470

EN
21/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akcea Therapeutics Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Akcea и Ionis объявляют о публикации долгос...

Akcea и Ionis объявляют о публикации долгосрочных клинических данных TEGSEDI® у пациентов с полиневропатией, вызванной наследственным транстиретин-амилоидозом, демонстрирующих устойчивые улучшения и даже большую стабилизацию у пациентов, приступающих к лечению раньше других. Результаты продолжающегося открытого дополнительного (OLE) исследования  краеугольного исследования NEURO-TTR, опубликованного в Европейском журнале неврологии, показывают, что у пациентов, принимавших TEGSEDI® (инотерсен), наблюдались устойчивое улучшение невропатического прогрессирования через 39 месяцев терапии и кли...

 PRESS RELEASE

Akcea et Ionis annoncent la publication de données cliniques à long ...

Akcea et Ionis annoncent la publication de données cliniques à long terme sur le TEGSEDI® chez des patients atteints de polyneuropathie causée par une amylose héréditaire liée à la transthyrétine démontrant des améliorations durables et une meilleure stabilisation des patients qui débutent le traitement plus tôt Les résultats de l'étude de prolongation ouverte (EPO) de l'essai pivot NEURO-TTR publiés dans la revue European Journal of Neurology montrent que les patients traités avec le TEGSEDI® (inotersen) ont bénéficié d'améliorations durables des mesures de l'évolution neuropathique après ...

 PRESS RELEASE

Akcea en Ionis kondigen publicatie aan van klinische langetermijngegev...

Akcea en Ionis kondigen publicatie aan van klinische langetermijngegevens van TEGSEDI® bij patiënten met polyneuropathie veroorzaakt door hereditaire transthyretine-amyloïdose die aanhoudende verbeteringen en een nog grotere stabilisatie bij patiënten die eerder met de behandeling beginnen, aantoont Resultaten van het huidige, open-label extensie (OLE)-onderzoek van de NEURO-TTR hoofdstudie gepubliceerd in het European Journal of Neurology tonen aan dat patiënten die behandeld werden met TEGSEDI® (inotersen), bij 39 maanden therapie aanhoudende verbetering van neuropathische progressie en k...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch